Docking Studies on Isoform-Specific Inhibition of Phosphoinositide-3-Kinases
暂无分享,去创建一个
Dima A. Sabbah | Jonathan L. Vennerstrom | Haizhen Zhong | J. Vennerstrom | Haizhen A. Zhong | D. Sabbah
[1] M. Lambert,et al. A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5 , 1993, Nature.
[2] Li Zhao,et al. Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.
[3] L. Toral-Barza,et al. Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy. , 2008, Journal of medicinal chemistry.
[4] R. Copeland,et al. Effects of oncogenic p 110 α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase , 2007 .
[5] Kaushik Raha,et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. , 2010, ACS medicinal chemistry letters.
[6] Sophie Gale,et al. 28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics. , 2010, IDrugs : the investigational drugs journal.
[7] H. Carlson,et al. Computational studies and peptidomimetic design for the human p53–MDM2 complex , 2004, Proteins.
[8] Q. She,et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] S. Andreola,et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] M. Zvelebil,et al. Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. , 2008, Archives of biochemistry and biophysics.
[11] Yigong Shi,et al. Structural analysis of a functional DIAP1 fragment bound to grim and hid peptides. , 2001, Molecular cell.
[12] Daniela Gabriel,et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.
[13] R. Abraham,et al. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. , 2009, Journal of medicinal chemistry.
[14] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[15] M. Waterfield,et al. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2- d ]pyrimidine derivatives as novel PI3 kinase p110α inhibitors , 2007 .
[16] H M Holden,et al. Carbamoyl phosphate synthetase: caught in the act of glutamine hydrolysis. , 1998, Biochemistry.
[17] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[18] J. Dodge,et al. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. , 1996, Journal of medicinal chemistry.
[19] Liisa Holm,et al. DaliLite workbench for protein structure comparison , 2000, Bioinform..
[20] M. Waterfield,et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. , 2006, Bioorganic & medicinal chemistry.
[21] NMR structure of the hypothetical protein encoded by the YjbJ gene from Escherichia coli , 2002, Proteins.
[22] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[23] K. Okkenhaug,et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. , 2001, Annual review of cell and developmental biology.
[24] Ya-wen Wang,et al. Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors , 2010, Journal of molecular modeling.
[25] L. Mario Amzel,et al. The Structure of a Human p 110 a / p 85 a Complex Elucidates the Effects of Oncogenic PI 3 K a Mutations , 2007 .
[26] Ming Han,et al. Class I Phospho-inositide-3-kinases (PI3Ks) Isoform-Specific Inhibition Study by the Combination of Docking and Molecular Dynamics Simulation , 2010, J. Chem. Inf. Model..
[27] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[28] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[29] M SoestvanR.W.,et al. Liphagal, a Selective Inhibitor of PI3 Kinase ά Isolated from the Sponge Aka coralliphaga: Structure Elucidation and Biomimetic Synthesis , 2006 .
[30] M. Waterfield,et al. Signaling by distinct classes of phosphoinositide 3-kinases. , 1999, Experimental cell research.
[31] L. Cantley,et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.
[32] K. Kinzler,et al. A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.
[33] Roger L. Williams,et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.
[34] W. Denny,et al. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110α inhibitors , 2007 .
[35] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .